Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204

Hussein Abdul-Hassan Tawbi, Peter A. J. Forsyth, Alain Patrick Algazi, Omid Hamid, F. Stephen Hodi, Stergios J. Moschos, Nikhil I. Khushalani, Rene Gonzalez, Christopher D. Lao, Michael Andrew Postow, Michael B. Atkins, Marc S. Ernstoff, Igor Puzanov, Ragini Reiney Kudchadkar, Reena Parada Thomas, Ahmad A. Tarhini, Joel Jiang, Alexandre Avila, Sheena Demelo, Kim Allyson Margolin

The University of Texas MD Anderson Cancer Center, Houston, TX
Moffitt Cancer Center and Research Institute, Tampa, FL
University of California, San Francisco, San Francisco, CA
The Angeles Clinic and Research Institute, Los Angeles, CA
Dana-Farber Cancer Institute, Boston, MA
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
University of Colorado Comprehensive Cancer Center, Aurora, CO
University of Michigan, Ann Arbor, MI
Memorial Sloan-Kettering Cancer Center and Weil Cornell Medical College, New York, NY
Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC
Roswell Park Cancer Institute, Buffalo, NY
Winship Cancer Institute, Atlanta, GA
Stanford University Hospital, Palo Alto, CA
University of Pittsburgh Medical Center, Pittsburgh, PA
Bristol-Myers Squibb, Princeton, NJ
Department of Medical Oncology, City of Hope, Duarte, CA